Skip to main
MLTX

MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target

MoonLake Immunotherapeutics (MLTX) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 31%
Hold 8%
Sell 0%
Strong Sell 15%

Bulls say

MoonLake is well-positioned in the rapidly growing market for immunology drugs and has a promising pipeline with diverse indications for SLK. While there is potential for competition, the positive results from clinical trials and differentiated profile of SLK set the company apart from its peers and may lead to further growth in the future. As MoonLake continues to progress through clinical trials and potentially receive regulatory approval for SLK, it could see an increase in revenue and profitability.

Bears say

MoonLake is a clinical-stage biotechnology company with a focused pipeline in inflammatory skin and joint diseases. However, the company faces significant regulatory and competition risks in its pursuit of approval and commercialization for its lead drug candidate, sonelokimab (SLK). The company's recent equity offering and upcoming data catalysts provide near-term support and potential upside, but the development and market potential for SLK in HS and other indications may be limited by competition and diversity in the clinical landscape. All of these factors contribute to a negative outlook on the company's stock.

MoonLake Immunotherapeutics (MLTX) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 31% recommend Buy, 8% suggest Holding, 0% advise Selling, and 15% predict a Strong Sell.

This aggregate rating is based on analysts' research of MoonLake Immunotherapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MoonLake Immunotherapeutics (MLTX) Forecast

Analysts have given MoonLake Immunotherapeutics (MLTX) a Buy based on their latest research and market trends.

According to 13 analysts, MoonLake Immunotherapeutics (MLTX) has a Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MoonLake Immunotherapeutics (MLTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.